Age-related macular degeneration (AMD) is a degenerative disease of the macula that leads to a progressive decline in central vision. Wet AMD requires treatment with intravitreal injections of antiangiogenic drugs, which can effectively slow down or even halt the disease's progression in many patients. These injections are also beneficial in the management of diabetic macular oedema by acting directly on the macula, reducing inflammation and fluid leakage.
At Barraquer, we have recently introduced a new generation medication to treat patients with either of these two conditions. This innovative drug, marketed under the name Vabysmo®, contains the active ingredient faricimab, a monoclonal antibody.
Unlike previous medications, this drug has a dual mechanism of action, significantly improving the effectiveness of treatment for diabetic macular oedema and wet AMD.
Its primary benefits can be summarized in two key points: potency and duration. First, it offers enhanced drying capability, making it more effective in reducing diabetic macular oedema and wet AMD.
Second, this medication provides a longer duration of action. This means fewer injections are required for effective disease control, resulting in improved disease management and greater patient compliance.
Dr. Santiago Abengoechea, ophthalmologist at the Barraquer Ophthalmology Centre